Journal article
Chi Yan, Nabil Saleh, Jinming Yang, C. Nebhan, A. Vilgelm, E. Reddy, Joseph T. Roland, Douglas B. Johnson, Sheau-Chiann Chen, R. Shattuck-Brandt, G. Ayers, A. Richmond
Molecular cancer, 2021
Molecular cancer, 2021
Semantic Scholar
DOI
PubMedCentral
PubMed
Cite
Cite
APA
Click to copy
Yan, C., Saleh, N., Yang, J., Nebhan, C., Vilgelm, A., Reddy, E., … Richmond, A. (2021). Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade. Molecular Cancer.
Chicago/Turabian
Click to copy
Yan, Chi, Nabil Saleh, Jinming Yang, C. Nebhan, A. Vilgelm, E. Reddy, Joseph T. Roland, et al. “Novel Induction of CD40 Expression by Tumor Cells with RAS/RAF/PI3K Pathway Inhibition Augments Response to Checkpoint Blockade.” Molecular cancer (2021).
MLA
Click to copy
Yan, Chi, et al. “Novel Induction of CD40 Expression by Tumor Cells with RAS/RAF/PI3K Pathway Inhibition Augments Response to Checkpoint Blockade.” Molecular Cancer, 2021.
BibTeX Click to copy
@article{chi2021a,
title = {Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade},
year = {2021},
journal = {Molecular cancer},
author = {Yan, Chi and Saleh, Nabil and Yang, Jinming and Nebhan, C. and Vilgelm, A. and Reddy, E. and Roland, Joseph T. and Johnson, Douglas B. and Chen, Sheau-Chiann and Shattuck-Brandt, R. and Ayers, G. and Richmond, A.}
}
Abstract
Background While immune checkpoint blockade (ICB) is the current first-line treatment for metastatic melanoma, it is effective for ~ 52% of patients and has dangerous side effects. The objective here was to identify the feasibility and mechanism of RAS/RAF/PI3K pathway inhibition in melanoma to sensitize tumors to ICB therapy. Methods Rigosertib (RGS) is a non-ATP-competitive small molecule RAS mimetic. RGS monotherapy or in combination therapy with ICB were investigated using immunocompetent mouse models of BRAF wt and BRAF mut melanoma and analyzed in reference to patient data. Results RGS treatment (300 mg/kg) was well tolerated in mice and resulted in ~ 50% inhibition of tumor growth as monotherapy and ~ 70% inhibition in combination with αPD1 + αCTLA4. RGS-induced tumor growth inhibition depends on CD40 upregulation in melanoma cells followed by immunogenic cell death, leading to enriched dendritic cells and activated T cells in the tumor microenvironment. The RGS-initiated tumor suppression was partially reversed by either knockdown of CD40 expression in melanoma cells or depletion of CD8 + cytotoxic T cells. Treatment with either dabrafenib and trametinib or with RGS, increased CD40 + SOX10 + melanoma cells in the tumors of melanoma patients and patient-derived xenografts. High CD40 expression level correlates with beneficial T-cell responses and better survival in a TCGA dataset from melanoma patients. Expression of CD40 by melanoma cells is associated with therapeutic response to RAF/MEK inhibition and ICB. Conclusions Our data support the therapeutic use of RGS + αPD1 + αCTLA4 in RAS/RAF/PI3K pathway-activated melanomas and point to the need for clinical trials of RGS + ICB for melanoma patients who do not respond to ICB alone. Trial registration NCT01205815 (Sept 17, 2010). Graphical abstract
